India Buzz Feed News
Buisness

Profit increases by 5% at Sun Pharma in Q2 due to robust sales of a generic cancer medication

<p>Strong sales in its domestic and U.S. formulation operations propelled Sun Pharmaceutical Industries, India’s biggest pharmaceutical by revenue, to a larger-than-expected increase in second-quarter earnings on Wednesday.</p>
<p><img decoding=”async” class=”alignnone wp-image-262114″ src=”https://www.theindiaprint.com/wp-content/uploads/2023/11/theindiaprint.com-profit-increases-by-5-at-sun-pharma-in-q2-due-to-robust-sales-of-a-generic-cancer-.jpg” alt=”theindiaprint.com profit increases by 5 at sun pharma in q2 due to robust sales of a generic cancer” width=”1228″ height=”920″ srcset=”https://www.theindiaprint.com/wp-content/uploads/2023/11/theindiaprint.com-profit-increases-by-5-at-sun-pharma-in-q2-due-to-robust-sales-of-a-generic-cancer-.jpg 259w, https://www.theindiaprint.com/wp-content/uploads/2023/11/theindiaprint.com-profit-increases-by-5-at-sun-pharma-in-q2-due-to-robust-sales-of-a-generic-cancer–150×112.jpg 150w” sizes=”(max-width: 1228px) 100vw, 1228px” title=”Profit increases by 5% at Sun Pharma in Q2 due to robust sales of a generic cancer medication 6″><br />
For the quarter that ended on September 30, the combined net profit after tax increased to 23.76 billion rupees ($285.37 million) from 22.62 billion rupees the previous year.</p>
<p>Based on LSEG statistics, analysts had projected a net profit of 23.04 billion rupees on average.</p>
<p>During the quarter, sales from its India formulations increased 11.1% to 38.43 billion rupees, while sales from its U.S. formulations division increased 7.9% to 35.5 billion rupees.</p>
<p>According to Sun Pharma, the two companies make up 32% and 30% of overall revenues, respectively.</p>
<p>revenues of the company’s generic version of the well-known cancer medication Revlimid also account for a significant portion of overall revenues.</p>
<p>One of India’s oldest pharmaceutical companies, Mumbai-based Sun Pharma, which also produces well-known consumer healthcare items including vitamin tablets called Revital and pain treatment gel called Volini, reported an 11.3% increase in overall operating income to 121.92 billion rupees.</p>
<p>Founded in 1983, the firm produces over-the-counter pharmaceuticals, anti-retrovirals, active pharmaceutical components, and generics as well as specialized drugs for both acute and chronic therapies.</p>
<p>Due to robust U.S. demand, rival companies Cipla and Dr Reddy’s announced better-than-expected profits last week.</p>
<p>Following its results, Sun Pharma’s shares increased by 1.26%, while the Nifty 50 index fell by 0.35%.</p>
<p> </p>

Related posts

October saw a decrease in European inflation to 2.9% as a result of decreasing gasoline costs

The Odisha Cabinet authorized the NUA Odisha initiative, which aims to train 100,000 youngsters annually

Equity indexes decline due to persistent outflows of foreign funds and poor Asian markets